参考文献
［1］ 中国心血管健康与疾病报告编写组.《中国心血管健康与疾病报告2021》概要［J］.中国循环杂志,2022,37(6):553‑578.DOI:10.3969/j.issn.1000‑3614.2022.06.001.
［2］ Fernández‑Friera L, Peñalvo JL, Fernández‑Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle‑aged cohort: the pesa (progression of early subclinical atherosclerosis) study［J］. Circulation, 2015,131(24):2104‑2113. DOI: 10.1161/CIRCULATIONAHA.114.014310.
［3］ Libby P. The changing landscape of atherosclerosis［J］. Nature, 2021,592(7855):524‑533. DOI: 10.1038/s41586‑021‑03392‑8.
［4］ Ahmadi A, Argulian E, Leipsic J, et al. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state‑of‑the‑art review［J］. J Am Coll Cardiol, 2019,74(12):1608‑1617. DOI: 10.1016/j.jacc.2019.08.012.
［5］ Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid‑lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial［J］. JAMA, 2004,291(9):1071‑1080. DOI: 10.1001/jama.291.9.1071.
［6］ Kini AS, Baber U, Kovacic JC, et al. Changes in plaque lipid content after short‑term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid‑lowering therapy)［J］. J Am Coll Cardiol, 2013,62(1):21‑29. DOI: 10.1016/j.jacc.2013.03.058.
［7］ Budoff MJ, Lakshmanan S, Toth PP, et al. Cardiac CT angiography in current practice: An American society for preventive cardiology clinical practice statement☆［J］. Am J Prev Cardiol, 2022,9:100318. DOI: 10.1016/j.ajpc.2022.100318.
［8］ 中华心血管病杂志（网络版）编辑委员会. 动脉粥样硬化斑块的筛查与临床管理专家共识［J/OL］. 中华心血管病杂志（网络版），2022，5:e1000123.(2022‑08‑13)［2022‑08‑14］. http://www.cvjc.org.cn/index.php/Column/columncon/article_id/301. DOI:10.3760/cma.j.cn116031.2022.1000123.
［9］ Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease［J］. N Engl J Med, 2017,376(18):1713‑1722. DOI: 10.1056/NEJMoa1615664.
［10］ Wright RS, Ray KK, Raal FJ, et al. Pooled patient‑level analysis of Inclisiran trials in patients with familial hypercholesterolemia or atherosclerosis［J］. J Am Coll Cardiol, 2021,77(9):1182‑1193. DOI: 10.1016/j.jacc.2020.12.058.
［11］ Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin‑treated patients: the GLAGOV randomized clinical trial［J］. JAMA, 2016,316(22):2373‑2384. DOI: 10.1001/jama.2016.16951.
［12］ Nicholls SJ, Kataoka Y, Nissen SE, et al. Effect of evolocumab on coronary plaque phenotype and burden in statin‑treated patients following myocardial infarction［J］. JACC Cardiovasc Imaging, 2022,15(7):1308‑1321. DOI: 10.1016/j.jcmg.2022.03.002.
［13］ Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high‑intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN‑AMI randomized clinical trial［J］. JAMA, 2022,327(18):1771‑1781. DOI: 10.1001/jama.2022.5218.
